Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CTSV | O60911 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086859 | 1.00 | LMNA (0.43) | LMNAALDH1A1SMN1; SMN2KMT2AAKR1C4 | |
| SCHEMBL17008498 | 0.91 | CTSV (0.43) | LMNAALDH1A1SMN1; SMN2KMT2AAKR1C4 | |
| SCHEMBL31086848 | 0.91 | CTSV (0.43) | LMNAALDH1A1SMN1; SMN2KMT2AAKR1C4 | |
| SCHEMBL17008489 | 0.90 | ALDH1A1 (0.41) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL31086594 | 0.90 | ALDH1A1 (0.41) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL17008525 | 0.88 | MAPK14 (0.42) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL31086537 | 0.88 | MAPK14 (0.42) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL17008477 | 0.86 | MRGPRX4 (0.39) | LMNAALDH1A1KMT2AMAPTHCK | |
| SCHEMBL17008493 | 0.85 | ALDH1A1 (0.40) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL31086872 | 0.85 | ALDH1A1 (0.40) | LMNAALDH1A1SMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| CN-113264921-A | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-106573914-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3418279-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | Respivert Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-3105223-B1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LTD (GB) | 2018-09-12 | — | — | EP | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| EP-3105223-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121660-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121660-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | LMNA 3005/4885ALDH1A1 2498/4885SMN1; SMN2 4266/4885 |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | LMNA 3403/4885ALDH1A1 2021/4885SMN1; SMN2 4462/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | LMNA 3052/4885ALDH1A1 2565/4885SMN1; SMN2 4107/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | LMNA 3546/4885ALDH1A1 1165/4885SMN1; SMN2 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.